Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation
Hepatocellular carcinoma (HCC) is disease with a high mortality rate and limited treatment options. Alterations of fibroblast growth factor receptor 4 (FGFR4) has been regarded as an oncogenic driver for HCC and a promising target for HCC therapeutics. Herein, we report that GNF-7, a multi-targeted...
Guardado en:
Autores principales: | Yunju Nam, Injae Shin, Younghoon Kim, SeongShick Ryu, Namdoo Kim, Eunhye Ju, Taebo Sim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e355c3f209df48bb95c0874512458e1d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biological Significance and Targeting of the FGFR Axis in Cancer
por: Athina-Myrto Chioni, et al.
Publicado: (2021) -
FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells
por: Qiong Cheng, et al.
Publicado: (2021) -
CircARVCF Contributes to Cisplatin Resistance in Gastric Cancer by Altering miR-1205 and FGFR1
por: Ruirui Zhang, et al.
Publicado: (2021) -
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Simone Romagnoli, et al.
Publicado: (2021) -
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
por: Jakub Szymczyk, et al.
Publicado: (2021)